NASDAQ · Biotechnology

KRRO (KRRO) Stock

$10.72 +0.75% NASDAQ: KRRO Healthcare

Valuation

MetricValue
Price$10.72
Market Cap$106.70M
P/E Ratio-0.80
P/B Ratio1.95
P/S Ratio25.93
EPS (TTM)$-12.48
52-Week High$55.89
52-Week Low$5.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-229.41%
ROA-102.63%
ROCE-167.31%
Gross Margin-1466.67%
Operating Margin-1450.00%
Net Margin-29.54%
Debt/Equity0.36
Current Ratio6.83

Annual Financials (USD)

Metric20212022202320242025
Revenue$14.0M$0$0$2.0M$6.0M
Operating Profit$-84.0M$-59.0M$-85.0M$-92.0M$-87.0M
Net Profit$-85.0M$-58.0M$-81.0M$-84.0M$-117.0M
EPS$-4.94$-227.42$-53.08$-9.37$-12.48
Op Margin-597.3%——-4047.1%-1366.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$185.0M$74.0M$222.0M$226.0M$114.0M
Total Liabilities$55.0M$173.0M$52.0M$66.0M$62.0M
Cash$80.0M$37.0M$166.0M$56.0M$22.0M
Borrowings$46.0M$167.0M$33.0M$45.0M$43.0M

Latest News

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 10, 2026 Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock? Zacks · Jul 8, 2026 Korro Bio Insider Sold Shares Worth $1,542,970, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Korro Bio Insider Sold Shares Worth $2,458,582, According to a Recent SEC Filing MT Newswires · Jun 25, 2026 Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock? Zacks · Jun 19, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-32.0M$-54.0M$-67.0M$-60.0M$-79.0M
Investing Cash Flow$-44.0M$6.0M$3.0M$-141.0M$43.0M
Financing Cash Flow$0$0$25.0M$2.0M$0
Net Cash Flow$44.0M$-43.0M$132.0M$-114.0M$-34.0M
Free Cash Flow$-37.0M$-59.0M$-75.0M$-78.0M$-79.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-70.86%
Quick Ratio8.13
Interest Coverage—
Return 1Y2.35%
Return 3Y-62.62%
Return 5Y-96.65%

Ownership

Insiders Held1.00%
Institutions Held96.93%
Institutions Float Held97.91%
Institutional HolderSharesReport Date
Lynx1 Capital Management Lp1,538,2962026-03-31
NEA Management Company, LLC1,297,8932026-03-31
Atlas Venture Life Science Advisors, LLC 1,137,1492026-03-31
Balyasny Asset Management LP1,040,0542026-03-31
Venrock Adviser, LLC1,009,5002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALT $3.03 -1.30% -2.31 $267.42M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
ANNX $5.37 +0.75% -3.71 $879.83M 0.00%
ANRO $28.67 +0.70% -6.29 $1.01B 0.00%
AURA $7.06 -1.40% -4.35 $453.25M 0.00%

About KRRO

KRRO is led by CEO Ram Aiyar, employs 112 people, headquartered in US, publicly traded since 2019.

KRRO stock trades at $10.72 with a market capitalization of $106.70M. The stock is valued at a price-to-earnings (P/E) ratio of -0.80, price-to-book of 1.95, price-to-sales of 25.93. Over the past 52 weeks the stock has ranged between $5.20 and $55.89, and currently trades 80.8% below its 52-week high.

On profitability, KRRO generates a return on equity (ROE) of -229.41%, return on capital employed of -167.31%, an operating margin of -1450.00%, a net profit margin of -29.54%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides